Posted 5th June 2019 by Joshua Broomfield
Denise Anderson is president of the Health Information Sharing and Analysis Centre (H-ISAC), USA. She spoke to us about her perspective on Healthcare Cybersecurity, the value of information sharing, and the paradigm shift the industry requires in light of new risks brought about by rapid innovation.
Posted 1st May 2019 by Joshua Broomfield
Blockchain technology is still in its nascency in the healthcare industry. At Frost & Sullivan, we do research and consulting for leading pharmaceutical and diagnostic companies, and the digital solution vendors that are providing Blockchain solutions to end-users.
Posted 15th April 2019 by Joshua Broomfield
Merck, Sharp & Dohme operates a hub model with IT hubs in the US, Czech Republic, and Singapore.
All operations and important functions of IT are distributed within those three hubs. It ensures not only that we follow the standard model but also ensures the regional presence and cooperation with the sites in any region.
Posted 1st April 2019 by Joshua Broomfield
This is the second instalment of a two-part blog post from Jothi Dugar, one of the pioneers in the field of Cyber Security. Here, Jothi explains how her experience with integrative medicine has transformed her approach to Cyber Security in a healthcare setting.
Posted 25th March 2019 by Joshua Broomfield
This is the first instalment of a two-part blog post from Jothi Dugar, one of the pioneers in the field of Cyber Security. Here, Jothi shares her experience of Cyber Security and developing an Information Security Office in a healthcare setting.
Posted 4th March 2019 by Joshua Broomfield
Application of blockchain is no longer a concept known only to a few industries. What started with cryptocurrency in 2009 has come a long way since. Its capability for secure transactions has enabled it to find potential in industries such as banking where security is one of key concerns when it comes to digital transformation. Healthcare industry leaders are also waking up to this call and are now exploring ways to embrace the technology owing to the multiple possible use cases for the industry.
Failing Blockbuster Medicines, Eroding Operator Margins & Increased Pricing Pressures: What’s Next for Precision Medicine?
Posted 12th September 2018 by Jane Williams
The Precision Medicine and Biomarkers Leaders Summit: Europe takes place this week and in anticipation, we spoke to Unmesh Lal of Frost and Sullivan about his views on what the future holds for precision medicine and how the pharmaceutical industry has changed in recent times.